Kirkland Represents GL Capital on Proposed Privatization of SciClone Pharmaceuticals
Kirkland & Ellis is advising GL Capital as the offeror on its proposed privatization of SciClone Pharmaceuticals (Holdings) Limited (HKSE: 6600), a company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange. The privatisation will be implemented by way of a scheme of arrangement. SciClone Pharmaceuticals is principally engaged in developing and commercializing a portfolio of marketed products and pipeline with potential in its focused therapeutic areas including oncology and severe infection. The transaction was announced on March 28, 2024.
Read GL Capital and SciClone Pharmaceuticals' joint announcement
The Kirkland team was led by corporate partner Joey Chau, with assistance from corporate associate Serene Lu. The team also included debt finance partners Jacqueline Zheng and Sean Zhang and investment funds partners Jennifer Feng and Shinong Wang and registered foreign lawyer Nicole Yang.
